pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
Immunology · news · pharmadog
← back to Immunology
News · Immunology
412
stories
23d
Publix recalls all lots of GreenWise Organic Frozen Blueberries and Whole Mixed Berries Due to potential E. coli O145 contamination
fda recalls
24d
GSK prepares for patent cliff with $2.5B cost-cutting plan
biopharma dive
24d
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
24d
An eye drug biotech banks $118M and stocks its executive suite
biopharma dive
24d
STAT+: From ‘lost cause’ to gold rush: Biotechs swarm to cure AATD
stat
25d
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug
biopharma dive
25d
Yarrow to begin trading as it targets Graves; FDA approves Otsuka's ADHD pill
endpoints
25d
Sarepta names former AbbVie R&D exec Michael Severino as next CEO
biospace
25d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
25d
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
biospace
25d
Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B
endpoints
25d
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
25d
From confidence to capital: Positioning biotech for the next growth cycle
biopharma dive
25d
STAT+: Argenx to buy Forte Biosciences for $2.2B
stat
25d
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug
fiercebiotech
25d
Lilly, AbbVie climb aboard in vivo CAR T train—but safety remains a hurdle
biospace
28d
There are already more U.S. measles cases this year than in all of 2025
stat
28d
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
28d
Sanofi halts development of troubled immune drug in eczema
biopharma dive
28d
Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped
biospace
28d
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
biospace
28d
Study of Yescarta patients reveals genetic red flags for CAR-T therapy side effects
fiercebiotech
28d
Baxter Issues Voluntary Nationwide Recall of Cefazolin in Dextrose Injection, USP, 2G / 100ml(20mg /ml) Single-Dose Infusion Bag in 100ml Due to Particulate Matter Found in Solution
fda recalls
28d
BAXTER ISSUES VOLUNTARY NATIONWIDE RECALL OF CEFAZOLIN IN DEXTROSE INJECTION, USP, 2G / 100ML (20MG / ML) SINGLE-DOSE INFUSION BAG IN 100ML DUE TO PARTICULATE MATTER FOUND IN SOLUTION
fda recalls
29d
Roche drops TCE for lupus, but hasn’t given up on autoimmune cell therapies
fiercebiotech
29d
Midwest Poultry Services. L.P. Recalls Shell Eggs Due to Possible Salmonella Enteritidis Contamination
fda recalls
29d
New study supports testing of Merck’s Ebola vaccine in DRC outbreak
stat
Jul 22, 26
Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
biopharma dive
Jul 22, 26
Summit and Akeso sharpen case for ivonescimab with new Western data
biospace
Jul 22, 26
Summit counters PD-1/VEGF skeptics; Celldex drug fails skin disease study
biopharma dive
← prev
page 5 of 14
next →
